Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol

Archives of Internal Medicine

Volumn 160, Issue 8, 2000, Pages 1177-1184

  Guyton, John R ^a   Blazing, Michael A ^a   Hagar, James ^b   Kashyap, Moti L ^b   Knopp, Robert H ^c   McKenney, James M ^d   Nash, David T ^e   Nash, Stephen D ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Veterans Affair Medical Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d National Clinical Research Inc   (United States)

^e Cholesterol Control Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; NICOTINIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLOW RELEASE FORMULATION; TREATMENT OUTCOME;

EID: 0034708959     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.8.1177     Document Type: Article

References (34)

1. Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human plasma, II: in atherosclerosis and related conditions. Am J Med. 1951;11:480-493.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714
3. Rhoads GG, Gulbrandsen CL, Kagan A. Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men, N Engl J Med. 1976;294: 293-298.
4. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso Heart-Study: high-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977;1:965-968.
5. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-381.
6. Assmann G, Schulte H, Von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124(suppl):S11-S20.
7. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
8. Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther. 1996;1:195-202.
9. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998;82:737-743
10. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47:1097-1104.
11. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B, IV: comparability of apolipoprotein B values by use of international reference material. Clin Chem. 1994;40:586-592.
12. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246-255.
13. Clauss A. Gerinnungphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-240.
14. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med. 1994;154:73-82
15. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642-650.
16. Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang ZQ, Ripsin CM. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991;151:1424-1432.
17. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 1994;121:252-258.
18. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271:672-677.
19. Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dL in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80:111-115.
20. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987; 317:1237-1245.
21. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lopid Coronary Angiography Trial (LOCAT) Study. Circulation. 1997;96:2137-2143.
22. Carlson LA, Oro L. Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis. 1973; 18:1-9.
23. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. 1983;67:730-734.
24. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
25. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
26. Broijersen A, Hamsten A, Silveira A, et al. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia, without influencing plasma fibrinogen. fibrin gel structure or coagulation factor VII. Thromb Haemost. 1996; 76:171-176.
27. Durrington PN, Mackness MI, Bhatnagar D, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type lib hyperlipoproteinaemia. Atherosclerosis. 1998;138:217-225.
28. Kockx M, de Maat MP, Knipscheer HC, et al. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients. Thromb Haemost. 1997;78:1167-1172.
29. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
30. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
31. Manninen V, Elo O, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
32. Kashyap ML. Mechanistic studies of high-density lipoproteins. Am J Cardiol. 1998; 82(suppl):42U-48U.
33. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
34. Personius BE, Brown BG, Gotto AM Jr, Little OM, Whitney EJ. Effects of increasing HDL-C, lowering triglyceride and lowering LDL-C on "fixed" atherosclerotic coronary artery disease: AFREGS (the Armed Forces Regression Study) [abstract]. Circulation. 1998;98(suppl I):I-450-I-451.